Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan could predict who benefits from esophageal cancer therapy

NCT ID NCT04359732

Knowledge-focused Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 21, 2026 · Updated 1 time

Summary

This study explores whether a special PET/MRI scan can predict how well esophageal cancer responds to chemotherapy and radiation given before surgery. Researchers will scan 121 patients during treatment and compare the images with the actual tumor response seen after surgery. The goal is to find imaging markers that identify responders early, potentially guiding more personalized care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hybrid PET/MRI scan
What this could lead to
If successful, this could help doctors personalize treatment by identifying which patients respond well to chemo-radiation before surgery.
What could go wrong
This is an observational imaging study, not a treatment trial. It may not change outcomes directly, and results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

121 people

The number who actually took part.

Started

May 2020

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * biopsy-proven esophageal or junctional carcinomas (either adenocarcinoma (AC) or squamous cell carcinoma (SCC) for which an Ivor-Lewis transthoracic esophagectomy with supramesocolic and mediastinal lymphadenectomy is indicated; * visible tumor on pre-treatment imaging; * ≥ 18 years of age; * signed informed consent. Exclusion Criteria: * \- incomplete preoperative imaging assessment; * contraindications to neoadjuvant treatment; * contraindications to preoperative imaging (such as pacemaker, allergy to contrast agents); * inability to complete imaging examinations (i.e. severe claustrophobia); * contraindication to surgery (comorbidities, distant metastatic disease (imaging confirmed)); * pregnant or lactating women * severe hypersensitivity to gadobutrol or fludeoxyglucose F18.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal adenocarcinoma esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma gastroesophageal junction adenocarcinoma neoplasm of esophagus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal cancer Esophageal neoplasms

Contacts and locations

Locations

  • Deaprtment of Radiology, IRCCS Ospedale San Raffaele

    Milan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.